Indeed, therapeutic approaches targeting IL-6 signaling in neoplasia have been successful in preclinical settings [61, 62], but anti-IL-6 monotherapy in clinical trials for colorectal, ovarian and pancreatic cancers showed no beneficial outcome [63], possibly because of signaling alterations. Here, IL6 is linked to familial pancreatic carcinoma.